Objective: This study aimed to explore the dynamics of the relationship among smartphone addiction, quality of life, and personality characteristics in university students. Method: This correlational and descriptive research was conducted to investigate the relationship between smartphone addiction, quality of life, and personality traits among university students. Using a nonprobability random sampling method, 496 university students were selected. Data collection involved the Student Information Form, Smartphone Addiction Scale, Symptom Checklist (SCL-90-R), Revised Eysenck Personality Questionnaire-Abridged Form (EPQR-A), and the WHO Quality of Life Scale-Short Form (WHOQOL-BREF). Statistical analysis was conducted with SPSS 25.0, utilizing Chi-square tests, independent sample t-tests, and Pearson's correlation analysis. Results: Out of 496 students (average age of 20.52), 59.87% were identified as smartphone addicts based on the Smartphone Addiction Scale-Short Version. A notable difference was found by study year (P = 0.009) and socioeconomic status (P = 0.003). Participants with smartphone addiction registered higher SCL-90-r scores for conditions like Obsessive Compulsive Disorder, Interpersonal Sensitivity, and Psychoticism. The Eysenck Personality Inventory highlighted that the Psychoticism score was significantly higher in the group with smartphone addiction (P = 0.001). A negative correlation between smartphone addiction scores and general health (WHOQoL) was identified, whereas a positive correlation with SCL-90-R's Psychoticism dimension score was observed (P < 0.001). Conclusion: Smartphone addiction is widespread among university student population. The study indicates that smartphone addiction not only impacts the individual's quality of life but also is associated with personality disorders, and these problems intensify with the severity of addiction. The findings underscore the need for interventions and educational programs to address smartphone addiction in this population.

Purpose: Attention-deficit/hyperactivity disorder (ADHD), a prevalent condition affecting 2.5– 5% of adults, impacting daily functioning. Sleep quality is essential for cognitive and socio-emotional well-being, and the association between ADHD symptoms and sleep disturbances necessitates identifying populations at risk. This study aimed to assess the associations between ADHD symptoms and sleep disorders by conducting a thorough assessment of sleep measures in a cross-sectional group of university students. Patients and Methods: Recruiting participants from a Turkish university (n=503; mean age=21.3 ± 1.8 years), subgroups were formed based on ADHD scores from the Adult ADHD Self-report Scale. Sleep was assessed using the Van Dream Anxiety Scale, Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Beck Depression Inventory (BDI) was employed to evaluate depressive symptoms. Results: ADHD symptoms group exhibited higher dream-related anxiety, PSQI, ESS, and BDI scores. Nightmares were more prevalent in the ADHD symptoms group. Subjective sleep measures showed differences in various domains, emphasizing poorer sleep quality in the ADHD symptoms group. Correlation analyses revealed intricate relationships between socio-economic factors, psychiatric health, family history, ADHD symptoms, nightmares, and sleep aspects. Conclusion: University students with ADHD symptoms face increased susceptibility to insufficient sleep, impacting daytime functioning and academic performance. Findings underscore the need for increased attention to sleep health in this population. Plain Language Summary: We wanted to understand how sleep problems affect university students who have symptoms of attention-deficit/hyperactivity disorder (ADHD). ADHD can make it harder to focus, stay organized, and manage time. People with ADHD often report having trouble sleeping, but we wanted to learn more about how sleep and mood might be linked to these symptoms. To do this, we asked students to fill out questionnaires about their sleep habits, feelings, and ADHD symptoms. We compared students with ADHD symptoms to those without. We found that students with ADHD symptoms: (1) Had more trouble falling or staying asleep, (2) Felt sleepier during the day, (3) Had more nightmares, (4) Reported feeling more depressed. We also discovered that poor sleep and low mood were strongly related to ADHD symptoms. In fact, sleep and mood explained about 68% of the differences in ADHD symptom levels. Students with ADHD symptoms were also more likely to sleep fewer hours than recommended. This can affect learning, memory, and daily life. Things like staying up late to study, using phones or computers at night, or having a busy social life may make sleep worse. Even though the study relied on self-reported answers and included students from only one university, the results suggest that better sleep and emotional support might help reduce ADHD symptoms and improve students’ well-being. Our research highlights the importance of supporting healthy sleep habits and mental health in students who experience attention difficulties.

Objective: Fibromyalgia Syndrome (FMS) is a chronic multifaceted condition characterized by widespread musculoskeletal pain, fatigue, cognitive difficulties, and emotional distress, predominantly affecting women. Although psychological factors are frequently implicated, their interrelations remain unclear. Key variables include alexithymia (particularly the difficulty identifying feelings [DIF] subdimension), somatosensory amplification (SSA), and mood symptoms. This study aimed to examine differences in alexithymia, anxiety, depression, and SSA between individuals with FMS and healthy controls, and explore how these variables relate within the FMS group.Methods: The study included 283 women (mean age = 31.84, SD = 4.02), comprising 142 FMS patients (mean age = 32.20, SD = 4.41) and 141 healthy controls (mean age = 31.48, SD = 3.58). Participants completed self-report measures assessing alexithymia, anxiety, depression, SSA, and functional impairment. Statistical analyses included independent samples t-tests and multivariate analyses of covariance (MANCOVA) to compare groups, and mediation analyses to examine indirect effects of anxiety and depression.Results: The FMS group reported significantly higher levels of anxiety, depression, DIF, and SSA compared to controls. However, after controlling for anxiety and depression, DIF differences were attenuated and SSA differences were no longer statistically significant. Within the FMS group, individuals with high alexithymic traits also exhibited higher SSA and mood symptoms; however, SSA elevations were no longer evident after accounting for anxiety and depression. Mediation analyses revealed that anxiety and depression significantly mediated the relationship between (a) DIF and functional impairment, and (b) SSA and functional impairment.Conclusion: Findings underscore the importance of emotional dysregulation and somatic sensitivity in FMS. Anxiety and depression appear to be key pathways linking these psychological traits to functional outcomes. Interventions aimed at improving emotional awareness and regulation may alleviate mood symptoms and enhance daily functioning in individuals with FMS.

Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır. Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejileri sayesinde her hastaya özgü bir şekilde planlanmaktadır. Tedavilerin bireyselleştirilmesi hususunda kuşkusuz yaş faktörünün önemi büyüktür ve tedavi kararlarında geriatrik popülasyon için seçilecek tedavi modalitesinin belirlenmesi oldukça hassas bir konudur. Zira tedavi seçeneklerinin herbirinin geriatrik popülasyonda kullanım şemaları, yan etki dağılımları ve yönetimleri farklılıklar göstermekte olup günlük pratiğimizde azımsanmayacak sıklıkta karşılaştığımız problemlerdendir.

Sosyal anksiyete bozukluğunun (SAB) farmakolojik tedavisinde, seçici serotonin geri alım inhibitörleri (SSRI) en sık reçete edilen ve üzerinde en çok klinik çalışma yapılan ajanlardır; tedavide tam etkinlikleri 16 haftayı bulabilir. Serotonin-norepinefrin geri alım inhibitörleri (SNRI) sınıfından venlafaksinin de benzer bir etkiye sahip olduğu bilinmektedir. Eski bir geçmişe sahip monoamin oksidaz inhibitörleri (MAOI) ise ciddi yan etkileri ve tiramin içeren gıdalarla ölümcül etkileşim riskinden dolayı diyet kısıtlaması gerektirdiği için sınırlı durumlarda tercih edilir. Benzodiazepinler ile gabapentin ve pregabalin gibi antikonvülzanlar da tedavide etkilidir ancak sedasyon, tolerans ve bağımlılık riskleri nedeniyle madde kullanım geçmişi olan hastalarda dikkatle izlenmelidir. Monoterapi ajanlarına kısmi yanıt veren hastalarda buspiron veya klonazepam ile güçlendirme tedavisi uygulanabilir. Hastalığın "yalnızca performans sırasında" ortaya çıkan alt tipinde ise genel tedavilerin aksine, performanstan 30 ila 60 dakika önce lüzum halinde kullanılmak üzere benzodiazepinler (klonazepam, lorazepam) veya fizyolojik belirtileri azaltan propranolol gibi beta-blokerler birinci basamak tedavi olarak reçete edilir. Pharmacological treatment of social anxiety disorder (SAD) primarily utilizes selective serotonin reuptake inhibitors (SSRIs), which are the most frequently prescribed agents, though their full efficacy may take up to 16 weeks to manifest. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), demonstrates comparable therapeutic effectiveness to SSRIs. While monoamine oxidase inhibitors (MAOIs) have a long history of use, their clinical utility remains limited by adverse effects and the strict requirement for a low-tyramine diet due to the risk of fatal hypertensive crises. Benzodiazepines, along with anticonvulsants like gabapentin and pregabalin, are effective but require careful monitoring due to risks of sedation, tolerance, and physical dependence. For patients showing partial response to monotherapy, augmentation strategies with buspirone or clonazepam can be implemented. Conversely, for the "performance-only" subtype of SAD, standard daily treatments are avoided; instead, short-acting benzodiazepines or beta-blockers such as propranolol are prescribed on an as-needed basis to be taken 30 to 60 minutes prior to a performance to manage acute physiological symptoms.